David Lewis

In a report released Wednesday, Morgan Stanley analyst David Lewis initiated coverage on Intuitive Surgical (NASDAQ: ISRG) with a base case of $370. Morgan Stanley previously had an Overweight rating. Analysts at Morgan Stanley believe Intuitive Surgical's improved procedures will result in...

In a report published Friday, Morgan Stanley analyst David Lewis maintained Equal-weight on Intuitive Surgical (NASDAQ: ISRG), with a NA price target. According to the report, the analyst's expectations were muted for the guide but our below the street EPS estimates are coming down 10 percent...

In a report published Thursday, Morgan Stanley analyst David Lewis maintained Overweight on Abbott Laboratories (NYSE: ABT), with a $45.00 price target. According to the report, guidance for 1Q and cash repatriation accounting created concerns, but the analysts remain focused on growth and...

In a report published Wednesday, Morgan Stanley analyst David Lewis maintained Equal-weight on Johnson & Johnson (NYSE: JNJ), with a NA price target, as 2014 looks promising. According to the report, performance in 2014 is dependent on continued pharma strength and leverage. The analysts are...

In a report published Friday, Morgan Stanley analyst David Lewis upgraded Abbott Laboratories (NYSE: ABT) to Overweight, with a $45.00 price target. According to the report, the upgrade reflects growth and leverage prospects into 2H14 and 2015 are underappreciated. Guidance for 2014 likely...

In a report published Monday, Morgan Stanley analyst David Lewis downgraded Hologic (NASDAQ: HOLX) from Overweight to Equal-weight and removed their $22.00 price target. Although there is a balanced risk-reward following recent stock appreciation, Lewis noted that Morgan Stanley's “SOTP analysis...

In a report published Monday, Morgan Stanley analyst David Lewis upgraded St. Jude Medical (NYSE: STJ) from Equal-weight to Overweight and announced a $75.00 price target. Lewis noted that Morgan Stanley is optimistic on guidance achievability in 2014 and St. Jude's pipeline. The analyst commented...

In a report published Monday, Morgan Stanley analyst David Lewis upgraded Boston Scientific (NYSE: BSX) from Equal-weight to Overweight based on pipeline acceleration traction. Despite disappointing pipeline progress in 2013 from Asthmatx reimbursement delays and S-ICD manufacturing constraints,...

In a report published Monday, Morgan Stanley analyst David Lewis upgraded Abbott Laboratories (NYSE: ABT) from Equal-weight to Overweight based on reacceleration. Lewis noted that Abbott's 2015 revenue is expected to grow more than 100 bp faster than the company's large cap peers. The analyst...

See more trading ideas here Equifax (NYSE: EFX) recently announced it is selling its Direct Marketing Services (DMS) unit to Alliance Data Systems (NYSE: ADS). This unit provides marketing information on 200 million US consumers. JP Morgan analysts Michael Meltz, David Lewis, and Nadia Lovell...

J.P. Morgan analysts David Lewis, Michael A. Meltz and Nadia Lovell reiterated their Overweight rating for shares of Gartner Inc (NYSE: IT), with a price target of $28 per share. One of the reasons the analysts like Gartner Inc shares is that they see potential upside from two of its recent...